Literature DB >> 29320899

In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A.

Kristyna Krasulova1, Zdenek Dvorak2, Pavel Anzenbacher1.   

Abstract

1. Itraconazole (ITZ), an antifungal azole derivate is a chiral drug that consists of four cis-diastereoisomers ((+)-2R,4S,2'R-ITZ-A; (+)-2R,4S,2'S-ITZ-B; (-)-2S,4R,2'S-ITZ-C and (-)-2S,4R,2'R-ITZ-D) which may differ in their pharmacokinetics and pharmacodynamics. 2. As ITZ is known as a CYP3A4 inhibitor causing severe drug-drug interaction, the inhibitory potencies of its individual optical isomers towards nine drug-metabolising cytochrome P450 (including CYP3A, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1), were investigated. 3. All ITZ diastereoisomers dose-dependently inhibited CYP3A activity in both used assays, midazolam and testosterone hydroxylation. The Ki values were assessed: for testosterone ITZ-A/0.085 µM; ITZ-B/0.91 µM, ITZ-C/0.20 µM and ITZ-D/0.022 µM; for midazolam ITZ-A/0.44 µM; ITZ-B/0.48 µM, ITZ-C/1.56 µM and ITZ-D/3.48 µM. The enzyme activity of CYP2C19 was moderately inhibited (IC50 30-53 µM), but in this case without large differences between the individual optical isomers. 4. The significant differences between diastereoisomers were presented. Antifungal potency of ITZ stereoisomers also differs so the potential enantiopure preparations of ITZ was not of interest.

Entities:  

Keywords:  Chiral drug; cytochrome P450; diastereoisomers; drug interaction; enzyme inhibition; itraconazole

Mesh:

Substances:

Year:  2018        PMID: 29320899     DOI: 10.1080/00498254.2018.1425510

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.

Authors:  Anne Gardin; Kasra Shakeri-Nejad; Andrea Feller; Felix Huth; Srikanth Neelakantham; Swati Dumitras
Journal:  Eur J Clin Pharmacol       Date:  2019-08-07       Impact factor: 2.953

2.  Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo.

Authors:  Li Wang; Fan Wu; Jia Xu; Yu Wang; Weidong Fei; Hui Jiang; Peiwu Geng; Quan Zhou; Shuanghu Wang; Yongquan Zheng; Huadong Deng
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.